Dr. Jorge Cortes joined Bio-Path’s Scientific Advisory Board as its chairman and an inaugural member. A well-established expert in oncology and hematology, Dr. Cortes currently holds several positions at the University of Texas MD Anderson Cancer Center, including Jane and John Justin Distinguished Chair in Leukemia Research, chief of the AML (acute myeloid leukemia) and CML (chronic myelogenous leukemia) sections, and deputy chair of the Leukemia department.
Over the course of his 25-year career specializing in leukemia research, Dr. Cortes has held several prestigious academic appointments at The University of Texas, including associate professor in the Leukemia department at the Graduate School of Biomedical Sciences and chair of the CML section at The University of Texas MD Anderson Cancer Center.
Dr. Cortes has also lent his experience as a consultant to leading pharmaceutical companies such as AstraZeneca on the development of prenyltransferase inhibitors, GlaxoSmithKline on the use of topotecan in MDS (myelodysplastic syndromes) and CMML (chronic myelomonocytic leukemia), and Rhône-Poulenc Rorer (now Sanofi-Aventis) on the use of PEG-asparaginase in adult ALL (acute lymphoblastic leukemia).
Dr. Cortes earned his medical degree from la Facultad de Medicina, Universidad Nacional Autónoma de México and a Bachelor of Science from el Centro Universitario México. He currently serves on the National CML Society’s Medical Advisory Board, as well as on numerous other executive committees and scientific advisory boards for organizations such as the Leukemia & Lymphoma Society and the International CML Foundation.
Dr. Hooper is a professor of cancer biology and neurological surgery and the section chief for translational research in the department of neurological surgery’s tumor division at Thomas Jefferson University. He has made important contributions to the understanding of immunity, particularly with respect to therapeutic and pathological mechanisms acting in central nervous system tissues, with over 140 peer-reviewed, full-length publications. Dr. Hooper’s work has led to novel immune therapies for rabies infection, neuroinflammation, and cancer with 10 issued U.S. patents and 19 international patents that have been licensed to five companies in the U.S. and abroad. He is the founding president of the Jefferson Chapter of the National Academy of Inventors and a fellow of the National Academy of Inventors. He is a co-founder of Imvax Inc., a startup company that has licensed Jefferson systemic cancer immunotherapy technology developed by Dr. Hooper and his colleagues. He serves on the editorial board of a number of journals including the Journal of Immunology and Scientific Reports and has been the recipient of numerous grants from the National Institutes of Health as well as other national and international agencies. Dr. Hooper received his doctorate in immunology from McGill University in Montreal, Quebec, Canada, and did his post-doctoral training at the University of Bristol, England.
Dr. Younes is a professor and chief of the Memorial Sloan Kettering’s Lymphoma Service. He has an extensive background in translational scientific research with a particular interest in targeted therapies. Prior to joining Memorial Sloan Kettering in 2013, he spent more than 20 years at M.D. Anderson Cancer Center, most recently as director of clinical and translational medicine in the department of lymphoma and myeloma.
Dr. Younes received his medical degree from the University of Damascus School of Medicine. He completed his internal medicine residency training at SUNY Downstate Medical Center and his pathology residency at the Medical College of Ohio. He completed his hematology fellowship training at Memorial Sloan Kettering.
Dr. Fleming is the chair and program director of the department of gastrointestinal oncology at Moffitt Cancer Center and a recognized leader in the treatment of gastrointestinal cancers. He initiated and developed the first direct xenograft program in gastrointestinal cancer at MD Anderson, providing a unique platform to examine pancreatic adenocarcinoma and to test new drug candidates for the treatment of pancreatic cancer. Prior to joining Moffitt, He was a professor in the department of surgical oncology at the University of Texas MD Anderson Cancer Center, where he served as chief of pancreas surgery and executive director of perioperative services.
Beyond his academic obligations, Dr. Fleming serves as an editor for numerous scientific journals including the Journal of Surgical Education, and serves on the editorial board of the Self-Assessment Program (SESAP) for the American College of Surgeons. During his career, he has written more than 130 peer-reviewed articles and 14 books. In addition, he has been recognized as a Castle Connolly Top Doctor since 2013 and included in the Consumer Research Council of America Guide to America's Top Surgeons since 2012.
Dr. Fleming received his M.D. from the University of Tennessee Center of Health Science. He completed his clinical residency in general surgery at the University of Texas Southwestern Medical Center, a fellowship at the University of Texas Southwestern Medical Center and a clinical fellowship in surgical oncology at the University of Texas MD Anderson Cancer Center.